Drugs / G-CSF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT06329999 Background | Feb 2024 → Dec 2025 overdue | acute myeloid leukemia, myelodysplastic syndrome | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF | “G-CSF starts at 5ug/kg, H, d0” NCT06329999 ↗ |
| Route | Subcutaneous | “subcutaneous injection of cytarabine and G-CSF combined with Venetoclax” NCT06329999 ↗ |